Logo image of TMBR

TIMBER PHARMACEUTICALS INC (TMBR) Stock Fundamental Analysis

NYSEARCA:TMBR - NYSE Arca - US8870802084 - Common Stock - Currency: USD

0.3426  +0 (+0.74%)

Premarket: 0.3532 +0.01 (+3.09%)

Fundamental Rating

2

Overall TMBR gets a fundamental rating of 2 out of 10. We evaluated TMBR against 193 industry peers in the Pharmaceuticals industry. While TMBR seems to be doing ok healthwise, there are quite some concerns on its profitability. TMBR does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

TMBR had negative earnings in the past year.
TMBR had a negative operating cash flow in the past year.
TMBR had negative earnings in each of the past 5 years.
TMBR had a negative operating cash flow in each of the past 5 years.
TMBR Yearly Net Income VS EBIT VS OCF VS FCFTMBR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -5M -10M -15M

1.2 Ratios

TMBR has a worse Return On Assets (-116.71%) than 84.31% of its industry peers.
Looking at the Return On Equity, with a value of -195.55%, TMBR is doing worse than 73.04% of the companies in the same industry.
Industry RankSector Rank
ROA -116.71%
ROE -195.55%
ROIC N/A
ROA(3y)-234.54%
ROA(5y)-276.44%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TMBR Yearly ROA, ROE, ROICTMBR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 1K -1K 2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TMBR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TMBR Yearly Profit, Operating, Gross MarginsTMBR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 -5K -10K -15K -20K -25K

More info and screens

6

2. Health

2.1 Basic Checks

TMBR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TMBR has been increased compared to 1 year ago.
There is no outstanding debt for TMBR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TMBR Yearly Shares OutstandingTMBR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 500K 1M 1.5M 2M 2.5M
TMBR Yearly Total Debt VS Total AssetsTMBR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M

2.2 Solvency

TMBR has an Altman-Z score of -7.84. This is a bad value and indicates that TMBR is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of TMBR (-7.84) is worse than 74.02% of its industry peers.
TMBR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.84
ROIC/WACCN/A
WACC9.15%
TMBR Yearly LT Debt VS Equity VS FCFTMBR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 5M -5M 10M -10M -15M

2.3 Liquidity

TMBR has a Current Ratio of 2.45. This indicates that TMBR is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.45, TMBR is doing worse than 63.24% of the companies in the same industry.
A Quick Ratio of 2.45 indicates that TMBR has no problem at all paying its short term obligations.
TMBR has a Quick ratio of 2.45. This is comparable to the rest of the industry: TMBR outperforms 41.67% of its industry peers.
Industry RankSector Rank
Current Ratio 2.45
Quick Ratio 2.45
TMBR Yearly Current Assets VS Current LiabilitesTMBR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 58.02% over the past year.
The Revenue for TMBR has decreased by -100.00% in the past year. This is quite bad
TMBR shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -4.36% yearly.
EPS 1Y (TTM)58.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-0.09%
Revenue 1Y (TTM)-100%
Revenue growth 3Y10.06%
Revenue growth 5Y-4.36%
Sales Q2Q%N/A

3.2 Future

TMBR is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -438.52% yearly.
Based on estimates for the next years, TMBR will show a very negative growth in Revenue. The Revenue will decrease by -41.42% on average per year.
EPS Next Y-2636.84%
EPS Next 2Y-438.52%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
TMBR Yearly Revenue VS EstimatesTMBR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2017 2018 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K
TMBR Yearly EPS VS EstimatesTMBR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TMBR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TMBR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TMBR Price Earnings VS Forward Price EarningsTMBR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TMBR Per share dataTMBR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

A cheap valuation may be justified as TMBR's earnings are expected to decrease with -438.52% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-438.52%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

TMBR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TIMBER PHARMACEUTICALS INC

NYSEARCA:TMBR (11/28/2023, 8:04:00 PM)

Premarket: 0.3532 +0.01 (+3.09%)

0.3426

+0 (+0.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14 2023-11-14/amc
Earnings (Next)03-29 2024-03-29/amc
Inst Owners1.48%
Inst Owner Change-0.01%
Ins Owners122.59%
Ins Owner Change0%
Market Cap1.04M
Analysts43.33
Price Target11.22 (3174.96%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-76.27%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.14
P/tB 0.14
EV/EBITDA N/A
EPS(TTM)-5.88
EYN/A
EPS(NY)-5.62
Fwd EYN/A
FCF(TTM)-5.2
FCFYN/A
OCF(TTM)-5.2
OCFYN/A
SpS0
BVpS2.5
TBVpS2.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -116.71%
ROE -195.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-234.54%
ROA(5y)-276.44%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 203.07%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.45
Quick Ratio 2.45
Altman-Z -7.84
F-Score3
WACC9.15%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-0.09%
EPS Next Y-2636.84%
EPS Next 2Y-438.52%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3Y10.06%
Revenue growth 5Y-4.36%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y21.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-82.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-83.04%
OCF growth 3YN/A
OCF growth 5YN/A